在存在风险的退伍军人中识别和治疗代谢功能障碍相关脂肪性肝病
研究评估了退伍军人健康管理局医疗中退伍军人代谢功能障碍相关脂肪性肝病(MASLD)危险因素的患病率、与MASLD诊断相关的因素以及MASLD诊断与接受诊疗之间的关联。MASLD诊断与参加体重管理项目、接受肝病专科诊疗及开具胰高血糖素样肽-1(GLP-1)类似物处方显著相关。
要点
- 存在风险的退伍军人中仅6%被诊断为MASLD或肝硬化。
- 1年随访中,6%参与体重管理项目,9%接受肝病专科诊疗,3%开具GLP-1类似物,2%接受分期弹性成像。
核心结论
- 很少有存在风险的退伍军人被诊断为MASLD或接受分期弹性成像。
- MASLD诊断与肝病专科诊疗和体重管理服务的衔接相关,亟需实施针对MASLD的人群筛查和管理服务。
研究设计与样本
- 利用国际疾病分类第10版代码识别2019年至2022年间在退伍军人健康管理局医疗中具有肥胖、糖尿病前期、糖尿病或血脂异常等MASLD危险因素的退伍军人。
- 采用多变量逻辑回归和倾向评分调整模型分析与MASLD或肝硬化诊断以及接受弹性成像、肝病专科诊疗、退伍军人健康管理局体重管理(MOVE!)参与和胰高血糖素样肽-1(GLP-1)类似物处方相关的人口学和临床特征。
主要发现
- 存在风险的队列中6%被诊断为MASLD或肝硬化。
- 被诊断为MASLD的存在风险退伍军人更年轻,代谢危险因素更多,酒精使用障碍比例更高,FIB-4评分和丙氨酸转氨酶值更高。
- 1年随访期间,6%参与MOVE!,9%接受肝病专科诊疗,3%被开具GLP-1类似物,2%接受分期弹性成像。
- MASLD诊断与接受MOVE!、专科咨询和GLP-1类似物处方显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD), an increasing public health concern, remains challenging to diagnose and risk-stratify. We assessed the (i) prevalence of MASLD risk factors among veterans in Veterans Health Administration (VA) care, (ii) factors associated with MASLD diagnosis, and (iii) associations between MASLD diagnosis and receipt of care. METHODS: Veterans with MASLD risk factors, including obesity, prediabetes, diabetes, or dyslipidemia, were identified using International Classification of Diseases-10 codes and followed in 2019-2022. Multivariable logistic regression and propensity score-adjusted models identified demographic and clinical characteristics associated with a diagnosis of MASLD or cirrhosis and receipt of elastography, specialty care for liver disease, VA weight management (MOVE!) participation, and glucagon-like peptide-1 (GLP-1) analog prescriptions. RESULTS: Among approximately 9 million veterans, 4,159,699 (45%) had risk factors for MASLD and were included in further analysis. MASLD or cirrhosis was diagnosed in 6% of the at-risk cohort. At-risk Veterans diagnosed with MASLD were younger with more metabolic risk factors, increased rates of alcohol use disorder, and higher FIB-4 scores and alanine transaminase values. Over 1-year follow-up, 6% engaged in MOVE!, 9% had specialty care for liver disease, 3% were prescribed GLP-1 analogs, and 2% underwent staging elastography. MASLD diagnosis was significantly associated with receipt of MOVE!, specialty care consultation, and GLP-1 analog prescription. DISCUSSION: Few at-risk Veterans carried an MASLD diagnosis or had undergone staging elastography. Because MASLD diagnosis was associated with linkage to hepatology care and weight loss therapy services, implementation of population screening and management services for MASLD is critically needed.
引用
- Niezen S, Morgan TR, Scott D, et al. Identifying and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Among At-Risk Veterans. Am J Gastroenterol. 2025. PMID: 39774063. doi:10.14309/ajg.0000000000003312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。